This house would allow the production of generic drugs

A generic drug is "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended use"1. India, Brazil, Thailand, South Africa and even smaller African countries such as Zambia, Ghana, Tanzania, Uganda and Zimbabwe produce generic drugs2. The production of generic drugs is a controversial issue due to the existence of patent protections on most pharmaceutical products that current law considers to be the property of the firms that produced them. Proponents of generic drugs point out the extremely high prices charged for brand name drugs as compared to generics when they are permitted, as well as the needs of the developing world for cheap drugs in their battle with various life-threatening diseases as reasons to circumvent conventional patent law and to permit the production of generics generally. Opponents of generic drugs hold that the patent rights are essential in order to encourage pharmaceutical companies to develop new and better drugs and that generic drugs are potentially harmful. Debates center around the issues of the inviolability of patents, the needs of the developing world for drugs and how best to meet them, and whether generic drugs can be a suitable and cheaper alternative to conventional brand name drugs.

1 Sherwood, Edward. 2011. "Generic Drugs". Center for Drug Evaluation and Research. Available:
2 Avert.org, "AIDS, Drug Prices and Generic Drugs",

Bibliography 

Avert.org, "AIDS, Drug Prices and Generic Drugs", Boseley, Sarah. 2006. "Rich Countries 'Blocking Cheap Drugs for Developing World'". The Guardian. Business Line. 2007. "Patents Grant Freedom to Invent Around". Hindu Business Line.Childs, Dan. 2007. "Generic Drugs: Dangerous Differences?". ABC News. Office. 2006. Research and Development in the PharmaceuticalIndustry". The Congress of the United States.  Fitzgerald, Brian and Anne Fitzgerald. 2004. Intellectual Property: In Principle.Melbourne: Lawbook Company.Faunce, Thomas. 2004. "The Awful Truth About Evergreening". The Age. Fitzgerald, Brian and Anne Fitzgerald. 2004. Intellectual Property: In Principle.Melbourne: Lawbook Company.Flanders Today. 2010. "Big Pharma Denies Strategic Shortages". Flanders Today. Gabb, Sean. 2005. "Market Failure and the Pharmaceutical Industry: A Proposal forReform". National Health Federation.  Institute for Prospective Technological Studies. 2009. "The 2009 EU Industrial R&DInvestment Socreboard". Economics of Industrial Research and Innovation. Kinsella, Stephan. 2010. "Patents Kill: Compulsory Licenses and Genzyme's Life-SavingDrug". Mises Institute.  Lee, Timothy. 2007. "Patent Rent-Seeking". Cato at Liberty.  Masia, Neal, 2008, "The Cost of Developing a New Drug", Focus on Intellectual Property Rights, America.gov,  Markey, Justice Howard. 1975. Special Problems in Patent Cases, 66 F.R.D. 529.Mercer, Illana. 2001. "Patent Wrongs". Mises Daily.  Mercurio, Bryan. 2007. "Resolving the Public Health Crisis in the Developing World:Problems and Barriers of Access to Essential Medicines". NorthwesternUniversity Journal of International Human Rights.  Nicol, Dianne and Jane Nielsen. 2003. "Patents and Medical Biotechnology: Empirical Analysis of Issues Facing the Australian Industry". Center for Law and GeneticsOccasional Paper 6.  Rockwell, Llewellyn. 2011. "The Google Pharm Case". Mises Daily.  "Generic Drugs". Center for Drug Evaluation and Research. Stim, Rishand. 2006. Profit from Your Idea: How to Make Smart Licensing Decisions.Berkeley: Nolo.United Nations. 2006. "Country Program Outline for Swaziland, 2006-2010". United Nations Development Program. World Intellectual Property Organization. 2011. "Emerging Issues in IntellectualProperty". Yale Law & Technology. 2011, "Patents: Essential, if flawed"

+

Or log in with...